Table 2.

Biochemical promoters of renal stone formation assessed in patients on drug management with topiramate

Parameter	Disclosed	Not disclosed	References
Hypercalciuria	34	31	[20], [23], [24], [46], [47], [49], [54]
Hyperoxaluria	15	56	[20], [23], [24], [45], [47], [49]
Hyperuricosuria	1	52	[23], [24], [47], [49]
Hypocitraturia	67	0	[20], [23], [24], [46], [47], [49], [53], [54]